Proteus Digital Health

By Jonah Comstock November 17, 2017
Correction: An earlier version of this article was unclear about differences between Abilify MyCite and the Proteus Digital Medicine Platform.  Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and...
By Dave Muoio November 15, 2017
Connected wearable patch makers will ship 35.1 million units annually by 2022, with 80 percent of these being used in clinical applications, according to a recent report from market intelligence firm Tractica. The report also forecasts a total $7.9 billion in revenue for the patch market by the same year, all of which suggests a substantial escalation from the 966,000 units the analysts wrote...
By Jonah Comstock September 7, 2017
Proteus Digital Health has made a high-profile addition to its board of directors: Dr. Regina Benjamin, who served as US Surgeon General from 2009 to 2013. "I am honored and excited to join the board of Proteus Digital Health,” Benjamin said in a statement. “As a nation, we are facing increasing challenges with chronic illnesses such as hypertension, diabetes, heart disease, hepatitis, behavioral...
By Jonah Comstock May 23, 2017
One year after the FDA declined to approve Proteus Digital Health and Otsuka's new sensor-embedded formulation of Otsuka's antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. As before, the application is a New Drug Application (NDA) -- both the Proteus system itself and Abilify are already FDA cleared and approved,...
By Jonah Comstock February 22, 2017
The Proteus Discover digital health system uses an ingestible sensor embedded in a pill to record data about – among other things – patients’ medication adherence. The sensor sends data to an adhesive patch, which in turn sends it to a mobile device. But what are the use cases that require that kind of precision and reliability? For the Children’s Health, a system of pediatric hospitals in the...
By Jonah Comstock August 22, 2016
Proteus Digital Health is working with Children's Health in Dallas, Texas in one of the first trials of its ingestible sensor technology in pediatric patients, The Dallas Morning News reports. The trial involves patients recovering from an organ transplant, a group that typically needs to take a lot of medications on a fairly strict schedule. Fifteen patients are using the Proteus platform now...
By Jonah Comstock May 12, 2016
April was a big month for digital health funding, with 15 more deals coming through, totalling an impressive $220 million and bringing the total funding so far this year to $691 million. As we did in February with Oscar, we're excluding the largest deal, Bright Health's $80 million round, from the total because the company in question is a tech-saavy payer, but not a digital health company per se...
By Jonah Comstock April 27, 2016
The FDA declined to approve what would have been the first mass market drug to incorporate Proteus Digital Health's ingestible sensor. The drug, a collaboration between Proteus and Otsuka Pharmaceuticals, combines the Proteus system with the antipsychotic pharmaceutical Abilify. “While we are disappointed in the FDA’s decision not to approve this digital medicine at this time, both Otsuka and...
By Aditi Pai April 15, 2016
Redwood City, California-based digital medicine company Proteus Digital Health has raised $50 million from undisclosed investors. The company’s existing investors include Medtronic, Itochu, St. Jude Medical, and Kaiser Permanente Ventures. This brings the company’s total funding to at least $450 million. The Proteus digital medicine platform, called Proteus Discover, is a medication management...
By Brian Dolan April 4, 2016
Proteus Digital Health announced interim study results from a randomized control study of its Proteus Discover timed with the American College of Cardiology event, ACC.16, in Chicago this week. The study included 96 patients with uncontrolled hypertension and type 2 diabetes and showed that a majority of the patients using the digital offering achieved the blood pressure target at week four. The...